Skip to Content

CLL14 study five-year results: Significantly superior efficacy for Ven-Obi

Five-year results from the ongoing CLL14 study, comparing venetoclax-obinutuzumab (Ven-Obi) to chlorambucil-obinutuzumab (Clb-Obi) in patients with previously untreated chronic lymphocytic leukemia (CLL), continue to demonstrate superior efficacy with longer progression-free survival (PFS) in patients receiving Ven-Obi. Let the primary investigator Dr. Othman Al-Sawaf update you in this MEDtalk.

Othman Al-sawaf

Få tilgang til artikkelen

Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.

Back to top